Biocept Awarded Patent in Canada for its Target Selector CTC Platform

SAN DIEGO, Aug. 2, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been awarded Canadian Patent No. 2,658,336 entitled, Detection or Isolation of Target Molecules Using a Microchannel Apparatus. The issued patent covers the use of Biocept's proprietary microchannels for the capture and detection of any target of interest. These targets include proteins and nucleic acids, as well as the capture of cancer cells or other cells that can be used for molecular analysis in blood and other biological fluids. 

"This patent issuance further expands the intellectual property protection of our liquid biopsy platform, which has the distinct advantage of using both CTCs and circulating tumor DNA (ctDNA) to detect and monitor biomarkers associated with cancer," said Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept.  "This broad patent covers the capture and detection of virtually any target molecule of interest using our unique microchannel technology, which disrupts the flow of fluids to improve biomarker capture."

Michael Nall, Biocept's President and CEO, added, "Broadening global patent protection for our Target Selector liquid biopsy platform is key to our strategy as we seek to develop our liquid biopsy business in international markets. We now have 28 issued patents covering our core technologies and plan to further strengthen our intellectual property position in additional geographies."

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer,  the utility and effectiveness of our intellectual property protections, and our ability to broaden the global patent protection for our Target Selector liquid biopsy platform and/or strengthen our intellectual property position in additional geographies, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.

View original content with multimedia:http://www.prnewswire.com/news-releases/biocept-awarded-patent-in-canada-for-its-target-selector-ctc-platform-300690815.html

SOURCE Biocept, Inc.

Investor Contact: LHA Investor Relations; Jody Cain; Jcain@lhai.com; 310-691-7100 OR Media Contact: Trevelino/Keller; Colleen Murphy; cmurphy@trevelinokeller.com; 404-214-0722, Ext. 109